What can we do about acute extrapyramidal symptoms?

Journal of Psychiatric and Mental Health Nursing

Volumn 7, Issue 3, 2000, Pages 205-211

  Gray, R ^a   Gournay, K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Extrapyramidal symptoms; Medication management; Nursing; Psychosis

Indexed keywords

NEUROLEPTIC AGENT;

CHEMICALLY INDUCED DISORDER; DYSKINESIA; HUMAN; METHODOLOGY; MUSCLE RIGIDITY; NURSING; PSYCHIATRIC NURSING; PSYCHOSIS; REVIEW;

ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MUSCLE RIGIDITY; PSYCHIATRIC NURSING; PSYCHOTIC DISORDERS;

EID: 0034209099     PISSN: 13510126     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2850.2000.00296.x     Document Type: Article

References (67)

1. Adler L.A., Angrist B., Rieter S. et al. (1989) Neuroleptic-induced akathisia: a review. Psychopharmacology 97, 1-11.
2. Ayd F.J. (1961) A survey of drug induced extrapyramidal reactions. JAMA 175, 1054-1060.
3. Baker L.A., Cheng I.Y., Amara I.E., et al. (1983) The withdrawal of benzotropine mesylate in chronic schizophrenic patients. British Journal of Psychiatry 143, 584-590.
4. Barnes T.R.E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
5. Barnes T.R.E. (1992) Clinical assessment of the extrapyramidal side effects of antipsychotic drugs. Journal of Psychopharmacology 6, 214-221.
6. Barnes T.R.E. & McPhillips M.A. (1996) Antipsychotic-induced extrapyramidal symptoms. Role of anticholinergic drugs in treatment. CNS Drugs 6, 315-330.
7. Bennett J., Done J. & Hunt B. (1995) Assessing the side effects of antipsychotic drugs: a survey of CPN practice. Journal of Psychiatric and Mental Health Nursing 2, 177-182.
8. Bermanzohn P.C. & Stris S.G. (1994) Noncompliance with anti-Parkinsonian medication in neuroleptic-treated schizophrenic patients: three case studies of an unreported phenomenon. Journal of Clinical Psychiatry 55, 488-491.
9. Bezchlibnyk-Butler K.Z. & Remington G.J. (1994) Anti-Parkinsonian drugs in the treatment of neurolpetic induced extrapyramidal symptoms. Canadian Journal of Psychiatry 39, 74-84.
10. Bigliani V. & Pilowsky L. (1999) In vivo neuropharmacology of schizophrenia. British Journal of Psychiatry 174 (Suppl. 38), 23-33.
11. Bigliani V., Mulligan R.S., Acton P.D. et al. (1999) In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]-epidepride single photon emission tomography (SPET) study. British Journal of Psychiatry 175, 231-238.
12. Boodhoo J.A. & Sandler M. (1991) Anticholinergic anti-Parkinsonian drugs in psychiatry. British Journal of Hospital Medicine 46, 167-169.
13. Borrison R.L. (1985) Amantadine in the management of extrapyramidal side effects. Clinical Neuropharmacology 6 (Suppl. 1), S57-S63.
14. Buchanan A. (1982) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychological Medicine 22, 787-797.
15. Casey D. (1991) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia Research 4, 109-120.
16. Casey D.E. (1996) Extrapyramidal syndromes. Epidemiology, Pathophysiology and the diagnostic dilemma. CNS Drugs 5 (Suppl. 1), 1-12.
17. Casey D.E. & Keepers G.A. (1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Psychopharmacology: Current Trends (eds Casey, D.E. & Christensen, A.V.). Springer, Berlin.
18. Chakos M.H., Mayerhoff D.I., Loebel A.D. et al. (1992) Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia. Psychopharmacology Bulletin 28, 81-86.
19. Chouinard G., Annable L., Ross-Chouinard A. et al. (1988) A five year prospective longitudinal study of tardive dyskinesia. Journal of Clinical Psychopharmacology 8, S21-S26.
20. Cook P.E., Dermer S.W. & McGurk T. (1986) Fatal overdose with amantadine. Canadian Journal of Psychiatry 31, 757-758.
21. Crown J. (1999) Review of Prescribing, Supply and Administration of Medicines. Department of Health, London.
22. Day J.C., Wood G., Dewey M. et al. (1995) A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry 166, 650-653.
23. DiMascio A., Bernardo D.L., Greenblatt D.J. et al. (1976) A controlled trial of amantadine in drug induced extrapyramidal disorders. Archieves of General Psychiatry 33, 599-602.
24. DoH (1999) The National Service Framework for Mental Health. The Stationary Office, London.
25. Drachman D.A. (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27, 783-790.
26. Fann W.E. & Lake C.R. (1976) Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced Parkinsonism. Archieves of General Psychiatry 33, 599-602.
27. Flischhacker W.W. (1991) Propranolol for fluoxetine-induced akathisia. Biological Psychiatry 30, 531-532.
28. Flischhacker W.W., Meise U., Günther V. et al. (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scandinivica 382, 11-15.
29. Gardos G., Cole J.O. & Tarsy D. (1978) Withdrawal syndrome associated with antipsychotic drugs. American Journal of Psychiatry 135, 1321-1324.
30. Garver D.L., Davis D.M., Dekirmenjian H. et al. (1976) Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology 47, 199-201.
31. Gerlach J. & Casey D.E. (1988) Tardive dyskinesia. Acta Psychiatrica Scandinivica 77, 369-378.
32. Goff D.C., Arana G.W, Greenblatt D.J. et al. (1991) The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double blind trial. Journal of Clinical Psychopharmacology 11, 106-112.
33. Goldman D. (1961) Parkinsonism and related phenomena from administration of drugs: their production and control under clinical conditions and possible relation to therapeutic effect. Review of Canadian Biology 20, 549-560.
34. Gray R., Smedley N. & Thomas B. (1997) The administration of PRN medication by mental health nurses. Journal of Psychiatric and Mental Health Nursing 4, 55-57.
35. Gray R. (1998) Primary care of schizophrenia what are the roles of practice and community psychiatric nurses. Community Mental Health 1, 5-7.
36. Gray R. (1999) Antipsychotics, side effects and effective management. Mental Health Care 2, 14-20.
37. Gray R., Parr A.-M., Plummer S. et al. (1999) A national survey of practice nurse involvement in mental health interventions. Journal of Advanced Nursing 30, 901-906.
38. Holister L.E., Chaffey E.M., Klett C.J. et al. (1960) Abnormal symptoms, signs and laboratory tests during treatment with phenothiazine derivatives. Clinical Pharmacology and Therapeutics 1, 284-293.
39. Jellinek T., Gardos G., Cole J.O. et al. (1981) Adverse effects of antiparkinson drug withdrawal. Archives of General Psychiatry 35, 483-489.
40. Kabes J., Sikora J., Pisvejc J. et al. (1982) Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. International Pharmacopsychiatry 17, 185-192.
41. Kane J.M. (1987) Treatment of schizophrenia. Schizophrenia Bulletin 13, 133-156.
42. 2 receptor occupancy with low dose haloperidol treatment: a PET study. American Journal of Psychiatry 153, 466-473.
43. Keepers G.A., Clappison V.J. & Casey D.E. (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry 40, 1113-1117.
44. Korsgaard S. & Friis T. (1986) Effects of mianserin in neuroleptic-induced Parkinsonism. Psychopharmacology 88, 109-111.
45. Kramer M.S., Gorkin R.A., DiJohnson C. et al. (1988) Propranol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenia: a double-blind placebo controlled study. Biological Psychiatry 24, 823-827.
46. Lavin M.R. & Rifkin A. (1991) Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of side effects. Journal of Clinical Pharmacology 31, 763-768.
47. Levinson D.F., Simpson G.M., Singh H. et al. (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of General Psychiatry 47, 761-768.
48. McEvoy J.P., Schooler N.R. & Wilson W.H. (1991) Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacological Bulletin 27, 97-101.
49. Mindham R.H.S. (1976) Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. British Journal of Clinical Pharmacology, 395-400.
50. Mindham R.H., Lamb P. & Bradley R. (1977) A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced Parkinsonism. British Journal of Psychiatry 130, 581-585.
51. Moore (1999) Behavioural pharmacology of the new generation of antipsychotic agents. British Journal of Psychaitry 174 (Suppl. 38), 5-11.
52. Nestelbaum Z., Siris S.G., Rifkin A. et al. (1986) Exacerbation of schizophrenia associated with amantadine. American Journal of Psychiatry 143, 1170-1171.
53. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Archives of General Psychiatry 49, 538-544.
54. Pearlman C.A. (1993) Akathisia as EPS. Journal of Clinical Psychiatry 54, 280.
55. Rego M.D. & Geller Jr, E.L. (1989) Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. Journal of Clinical Psychiatry 50, 143-144.
56. Remington G. & Bezchlibnyk-Butler K. (1996) Management of acute antipsychotic-induced extrapyramidal syndromes. CNS Drugs 5 (Suppl. 1), 21-35.
57. Rupniak N.M.J., Jenner P. & Marsden C.D. (1983) Acute dystonia induced by neuroleptic drugs. Psychopharmacology 88, 403-419.
58. Simpson G.M. & Angus J.W.S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinivica 212, 11-19.
59. Singh H., Levinson D.F., Simpson G.M. et al. (1990) Acute dystonia during fixed-dose neuroleptic treatment. Journal of Clinical Psychopharmacology 10, 389-396.
60. Spohn H.E. & Strauss M.E. (1989) Relation of neuroleptic dose and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology 98, 367-380.
61. Stenson R.L., Donlon P.T. & Meyer J.E. (1976) Comparison of benztropine mesylate and amantadine HCI in neuroleptic-induced extrapyramidal symptoms. Comprehensive Psychiatry 17, 763-768.
62. van Putten T. (1974) Why do schizophrenic patients refuse to take their medication? Archives of General Psychiatry 31, 67-72.
63. van Putten T., May P.R.A. & Marder S.A. (1984) Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 41, 1036-1039.
64. 2 receptor subtypes in relation to schizophrenia and neuroleptic drug action. Neuroscience 2, 89-92.
65. Weiden P.J., Shaw E. & Mann J. (1986) Causes of neuroleptic non-compliance. Psychiatric Annals 16, 571-578.
66. Winslow R.S., Stillner V., Coons D.J. & Robison M.W (1986) Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. American Journal of Psychiatry 143, 706-710.
67. Yassa R., Iskandar H. & Nastase C. (1988) Propranolol in the treatment of tradive akathisia: a review of two cases. Journal of Clinical Psychopharmacology 8, 283-285.